Recommended Free Tools
AI health assistants need to do two things at once: refuse requests that could cause harm and still answer ordinary health questions safely. Separately, the FDA’s January 2026 review found no increased risk of suicidal thoughts or behavior associated with GLP-1 medicines, but that finding does not mean the medicines have no side effects. The available studies do not show whether AI assistants answer questions about GLP-1 side effects accurately—or whether they refuse them.
Why pair AI refusals with weight-loss drug safety?
These are two distinct health-information issues, not evidence of a direct connection. Research on AI evaluates how assistants handle medical questions and potentially risky prompts. The FDA’s drug-safety communications address GLP-1 medicines and their use. Neither establishes how current AI systems respond to questions about these medicines specifically.
As an Amazon Associate I earn from qualifying purchases.
The shared concern is whether people can get useful, appropriately cautious information. A chatbot should not replace a clinician, and a refusal rate by itself cannot tell us whether its health responses are safe: refusing a benign question can leave someone without useful guidance, while answering a dangerous request can create harm.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsWhy do AI assistants refuse some harmless health questions?
Many safety systems draw boundaries around potentially harmful content. In health settings, a request can be ambiguous: a safe response may be possible at a high level, even when detailed instructions would be unsafe. Researchers call the failure to answer a benign request “over-refusal”; the opposite failure is unsafe compliance.
#1 Best Overall
Health-ORSC-Bench, published in Findings of ACL 2026 by Zhihao Zhang and coauthors, tested 30 language models on 31,920 benign boundary prompts across seven health categories. Its authors report that some safety-optimized models refused up to 80% of the benchmark’s “Hard” benign prompts. That figure describes performance on a constructed benchmark, not the share of real users whose health questions are refused.
The paper describes the underlying tension this way: “Safety alignment in Large Language Models is critical for healthcare; however, reliance on binary refusal boundaries often results in over-refusal of benign queries or unsafe compliance with harmful ones.”
Rank #2
What medical chatbot evaluations can—and cannot—show
A physician-led study published in npj Digital Medicine assessed 888 responses to 222 patient-posed medical questions from four public chatbots. The researchers collected most responses between September 10 and December 24, 2024; one response was collected on February 12, 2025, after a data-saving error. Physicians rated responses as acceptable or problematic.
This study illustrates why medical chatbot answers need safety evaluation, but its results are tied to the systems and responses tested at that time. They do not rank today’s systems, and the study did not test advice about GLP-1 side effects. A separate 2026 review in npj Digital Medicine argues that evaluation should examine both under-refusal and over-refusal. Its framework is not a clinical guideline or a measured result for a particular model.
Rank #3
What did the FDA find about GLP-1 medicines and suicidal thoughts?
In a Drug Safety Communication dated January 13, 2026, the FDA said its comprehensive review found no increased risk of suicidal ideation or behavior associated with GLP-1 receptor agonists. It asked the application holders for Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide) to remove the related warning from their labels. The agency said the earlier label language was based on reports involving older medicines used or studied for weight loss.
The FDA described two analyses:
| Evidence | Size | What the FDA reported |
|---|---|---|
| Placebo-controlled GLP-1 trials | 91 trials; 107,910 patients | The pooled results did not show increased risk of suicidal ideation or behavior, or of other relevant psychiatric adverse events, including anxiety, depression, irritability, or psychosis. |
| FDA Sentinel retrospective cohort | 2,243,138 users | After adjustment, the analysis found no increased intentional self-harm risk among new GLP-1 users compared with new users of SGLT2 inhibitors. |
These findings do not establish zero risk for every individual, nor do they say that GLP-1 medicines have no side effects. They address the specific psychiatric risks the FDA reviewed; they are not a comprehensive guide to every possible adverse effect.
Rank #4
What to do about mood changes
The FDA advises patients to take their medicine as prescribed and discuss concerns with a health professional. Tell a health professional about new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior. The FDA communication lists 988 for immediate crisis support and encourages patients and health professionals to report side effects through MedWatch.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Are compounded or unapproved GLP-1 products the same safety question?
No. The FDA’s review of suicidal ideation and behavior concerned GLP-1 medicines; its warnings about unapproved and compounded products concern separate risks, including whether a product has been reviewed for safety, effectiveness, and quality, and whether it is prepared, stored, labeled, and dosed correctly.
The FDA says compounded medicines should be used only when a patient’s medical needs cannot be met by an FDA-approved drug. It recommends a doctor’s prescription and a state-licensed pharmacy. As the agency puts it: “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”
The FDA has described reports of dosing errors involving compounded injectable semaglutide, including measurement and dose-calculation mistakes; some reports involved hospitalization. It has also received complaints about products arriving warm or with inadequate ice packs, fraudulent labeling, and possible use of semaglutide salt forms, which are different active ingredients from those in approved medicines. The agency says adverse events from compounded products are likely underreported because many state-licensed pharmacies are not required to submit reports.
As of May 31, 2026, the FDA reported receiving 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. These are reports, not incidence rates: they do not show how frequently an event occurs among users or prove that the drug caused it. The FDA cautions that it cannot always determine whether a reported event resulted directly from the drug or from other factors.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCan AI help people manage weight-loss treatment?
A retrospective study in Diabetes, Obesity and Metabolism examined an asynchronous AI support agent used in an Australian digital weight-loss service. It included 16,556 adults prescribed semaglutide between May 2024 and October 2025. The authors reported six-month adherence of 53.2% after the agent was introduced, compared with 47.3% in the pre-agent comparison.
Because this was an observational analysis, it cannot show that the AI agent caused the difference. It also does not establish that an AI system can identify side effects accurately or safely replace a clinician. The available evaluations and studies do not directly measure current AI responses to questions about GLP-1 side effects.
Quick Recap
How should you use an AI answer about a medicine?
- Use it for orientation, not a treatment decision. It may help you organize questions or understand general information, but do not start, stop, or change a prescribed medicine based on a chatbot response.
- Check which product the answer concerns. FDA-approved medicines and compounded products raise different safety questions; an answer that treats them as interchangeable is not giving you the distinction you need.
- Ask a health professional about personal symptoms or risks. A chatbot cannot assess your full medical history or determine the cause of a symptom from a short prompt.
- For urgent suicidal thoughts, seek immediate support. The FDA’s January 2026 communication lists 988 for immediate crisis support.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
